Drug Trial Radar · NCT04544436
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
864
Actual
Start
Nov 26, 2020
Primary completion
Dec 19, 2024
Study completion Apr 1, 2027
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Sep 10, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and PK of a higher dose of ocrelizumab per intravenous (IV) infusion every 24 weeks (Q24W) in participants with RMS, in comparison to the approved 600 milligrams (mg) dose of ocrelizumab.
Conditions
- Multiple Sclerosis
Interventions
OcrelizumabDrug
The actual higher dose of ocrelizumab will be assigned to participants based on their body weight at baseline: 1200 mg (body weight \<75 kg) or 1800 mg (body weight ≥ 75 kg). The first dose of ocrelizumab will be administered as two 600 mg or 900 mg IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 1200 mg or 1800 mg IV infusion Q24W. During the optional OLE phase, participants will continue with their assigned dose of ocrelizumab (either 1200 or 1800 mg) for approximately 96 weeks (4 doses in total).
OcrelizumabDrug
Ocrelizumab will be administered at a dose of 600 mg Q24W. The first dose of ocrelizumab will be administered as two 300 mg IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 600 mg IV infusion Q24W.
AntihistamineDrug
Premedication with oral or IV antihistaminic drug (i.e., diphenhydramine 50 mg or an equivalent dose of an alternative) will be administered prior to each ocrelizumab infusion.
MethylprednisoloneDrug
Premedication with 100 mg of methylprednisolone (or equivalent) will be administered by IV infusion prior to each ocrelizumab infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Onset of 12-week Composite Confirmed Disability Progression (cCDP12)Time frame: Up to approximately 4 years
Locations
121 sites in 21 countries. Site status is shown where the registry gives one.
North Central Neurology Associates
Cullman, Alabama
Alabama Neurology Associates
Homewood, Alabama
21st Century Neurology
Phoenix, Arizona
Profound Research, LLC
Carlsbad, California
Stanford University Medical Center
Stanford, California
Advanced Neurology of Colorado, LLC
Fort Collins, Colorado
Neurology Associates, PA
Maitland, Florida
University of South Florida
Tampa, Florida
American Health Network Institute, LLC
Avon, Indiana
University of Kansas Medical Center
Kansas City, Kansas
The NeuroMedical Clinic of Central Louisiana
Alexandria, Louisiana
Maine Medical Center
Scarborough, Maine
Dragonfly Research, LLC
Wellesley, Massachusetts
Henry Ford Health System
Detroit, Michigan
Washington University School of Medicine
St Louis, Missouri
Cleveland Clinic Lou Ruvo
Las Vegas, Nevada
Dent Neurological Institute
Amherst, New York
UC Health Neurology
Dayton, Ohio
Oklahoma Medical Research Foundation
Oklahoma City, Oklahoma
Abington Neurological Associates
Willow Grove, Pennsylvania
Tri-State Mountain Neurology
Johnson City, Tennessee
Hope Neurology
Knoxville, Tennessee
Bhupesh Dihenia M.D. P.A.
Lubbock, Texas
Lone Star Neurology of San Antonio
San Antonio, Texas
Evergreen MS Center
Kirkland, Washington
Centro de Especialidades Neurológicas y Rehabilitación - CENyR
Buenos Aires, Argentina
CEMIC
Buenos Aires, Argentina
Centro de Investigaciones Médicas Tucuman
San Miguel de Tucumán, Argentina
Austin Hospital
Heidelberg, Victoria, Australia
Hospital Erasme
Brussels, Belgium
Revalidatie en MS Centrum
Overpelt, Belgium
Instituto de Neurologia de Curitiba
Curitiba, Paraná, Brazil
IMV Pesquisa Neurológica
Porto Alegre, Rio Grande do Sul, Brazil
Clinica Neurologica
Joinville, Santa Catarina, Brazil
CPQuali Pesquisa Clinica Ltda
São Paulo, São Paulo, Brazil
Recherche Sepmus Inc.
Greenfield Park, Quebec, Canada
Centre de Recherche Saint-Louis
Lévis, Quebec, Canada
Rigshospitalet Glostrup
Glostrup Municipality, Denmark
Groupe Hospitalier Pellegrin
Bordeaux, France
CHU Hopital Gabriel Montpied
Clermont-Ferrand, France
Showing 40 of 121 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.